The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis
BackgroundThe lung immune prognostic index (LIPI) is recently developed to predict immune checkpoint inhibitors (ICIs) treatment outcomes for non-small cell lung cancer. However, its predictive value for other types of cancer remained unclear. This meta-analysis aimed to evaluate the association bet...
Main Authors: | Hui Liu, Xiao-Li Yang, Xiao-Yun Yang, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.691002/full |
Similar Items
-
Cancer-Specific Immune Prognostic Signature in Solid Tumors and Its Relation to Immune Checkpoint Therapies
by: Shaoli Das, et al.
Published: (2020-09-01) -
Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors
by: LI Tao, et al.
Published: (2023-05-01) -
Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
by: Qiang Su, et al.
Published: (2019-02-01) -
Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
by: Xue-lin Zou, et al.
Published: (2021-12-01) -
Clinical Value of Autoantibody Prognostic Markers in Tumor Immune Checkpoint
Inhibitor Therapy
by: Liyuan DAI, et al.
Published: (2022-07-01)